Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Marketing Status Prescription; Discontinued
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 66794-214; 71205-593; 68071-4713; 44567-702; 66794-215; 70518-3355; 68180-633; 0143-9859; 50090-0945; 63187-435; 66794-213; 64679-702; 64679-701; 25021-106; 0143-9678; 68180-622; 25021-105; 66794-212; 25021-107; 0264-3155; 44567-700; 64679-703; 66794-211; 44567-703; 0143-9856; 71205-117; 0143-9858; 68071-4715; 72572-061; 68180-611; 68071-4304; 64679-983; 68071-4303; 44567-701; 0264-3153; 0143-9857; 63323-346; 68180-644; 72572-062; 50090-2628
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transaminases increased13.03.01.0150.061278%Not Available
Foetal death18.01.02.003; 08.04.01.0110.005328%
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.0040.020426%Not Available
Intra-abdominal haematoma07.12.02.005; 24.07.02.0340.005328%Not Available
Paraesthesia oral17.02.06.008; 07.05.03.0030.061278%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.020426%Not Available
Staphylococcal infection11.02.05.0020.020426%Not Available
Pulseless electrical activity02.03.04.0200.020426%Not Available
Blood alkaline phosphatase increased13.04.02.0040.030639%
Drug resistance08.06.01.0050.042628%Not Available
Urine output decreased13.13.03.0010.051065%
Induration08.01.03.020--Not Available
Hepatic enzyme increased13.03.01.0190.091916%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Biliary tract disorder09.02.03.0010.020426%Not Available
Bladder disorder20.03.01.0020.020426%Not Available
Cardiac disorder02.01.01.003--Not Available
Enterococcal infection11.02.08.0020.020426%Not Available
Inflammation08.01.05.0070.061278%Not Available
Lung infection22.07.01.008; 11.01.09.0080.010657%
Intra-abdominal haemorrhage24.07.02.035; 07.12.02.0080.005328%
Ischaemia24.04.02.0040.030639%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal injury12.01.05.001; 20.01.03.0150.051065%Not Available
Ill-defined disorder08.01.03.049--Not Available
Autoimmune disorder10.04.04.0030.020426%
Disease progression08.01.03.038--
Drug intolerance08.06.01.013--Not Available
Hepatic lesion09.01.08.0050.040852%Not Available
The 16th Page    First    Pre   16 17 18    Next   Last    Total 18 Pages